Twitter   Facebook   e-Newsletters   Podcsts   RSS Feeds   Share

107,907
Adis R&D Insight

Last Loaded on Web: Tuesday, October 01, 2013

Last Update To Bluesheet: December 17, 2009

Bluesheet Contents     PDF version

File Description Dialog File Data Special Features Terms and Conditions Additional Indexes Map
Subject Coverage Document Types Indexed DIALINDEX/OneSearch Categories Sample Record Sort Predefined Format Options
Tips Geographic Coverage Contact Basic Index Rank Rates


File Description [top]

Adis R&D Insight comprehensively reports on the latest developments of drugs in active research and development internationally each week. More than 25,000 drugs are included in the database. Drugs reported in Adis R&D Insight start with the earliest laboratory report and continue through to world market launch. Every scientific or commercial development advancing the drug's progress to market is assessed, evaluated, and reported in Adis R&D Insight.

Adis R&D Insight is compiled from information collected from many sources. The primary sources are: direct contact with companies involved with research and development, information collected from drug and therapeutic literature published in more than 2,300 medical and biomedical journals, attendance at international meetings and conferences, company annual reports, news services, press releases, and licensed Lehman Brothers' PharmaPipelines data.

Adis editors check all the information before reporting in R&D Insight to ensure the integrity and timeliness of the published information.

File 107 is the public file; File 907 is the subscriber file, available to those who subscribe to a qualifying Wolters Kluwer Pharma Solutions product.



Tips [top]

USE FILE 107

to find R&D information on drug research from laboratory discovery to launch.

USE MAP

to extract CAS® Registry Numbers for searching in other pharmaceutical databases:

     MAP RN TEMP

EXPAND ON DP=

to choose a developmental phase:

     EXPAND DP=PHASE III

ENTER HELP CODES 107

to see WHO ATC and EphMRA ATC codes.

ENTER HELP EVAL 107

to find definitions of Adis Evaluation.



Subject Coverage [top]

Information reported in Adis R&D Insight includes: generic name, synonyms, brand names, developing companies, development phases by indication and country, adverse events, pharmacology, pharmacokinetics, pharmacodynamics, therapeutic trials, development history, licensed forecast information from Lehman Brothers, and Adis's own unique therapeutic value rating. Adis R&D Insight profiles are also backed by more than 10,000 evaluated Adis scientific summaries and 63,000 bibliographic references.


Dialog File Data [top]

Dates Covered: 1986 to present
File Size: 25,000+ records as of December 2009 (File 107)
and 25,000+ records as of December 2009 (File 907)
Update Frequency: Weekly


Document Types Indexed [top]

  • Reports


Geographic Coverage [top]

  • International


Geographic Restrictions [top]

  • None


Special Features [top]

  • ERA Available
  • KWIC and HILIGHT Available
  • DIALOG Alert Available
  • MAP Available


DialIndex/OneSearch Categories [top]

ACRONYM CATEGORY NAME
ADIS Adis Files
BRANDNMS Brand Names
CASREGNO CAS(R) Registry Numbers-Chemical and Medical Files
DRUGDEV Drug Development Pipeline
DRUGDIR Drug Directories
PHARM Pharmacology
PHARMR Pharmacology + RINGDOC-Files
PHARMREG Pharmaceutical Regulation


Contact [top]

Adis R&D Insight is provided by Wolters Kluwer Pharma Solutions. Questions concerning file content should be directed to:

Wolters Kluwer Pharma Solutions
Client Services Department
770 Township Line Road, Suite 300
Yardley, PA 19067

Telephone: +1-267-757-3421 ex 1
800 Line: 1-877-872-2347 ex 1
Fax: +1-267-757-0652
E-Mail: sarah.schweer@wolterskluwer.com
Wolters Kluwer Pharma Solutions
Client Services Department
250 Waterloo Road
London, SE1 8RD
United Kingdom
Telephone: +44 20 7981 0764
Fax: +44 20 7981 0564
E-Mail: sarah.schweer@wolterskluwer.com


Terms and Conditions [top]

For Dialog's Redistribution and Archive Policy, enter HELP ERA online. The following terms and conditions also apply.

Database copyrighted by Adis Data Information BV. Data may not be duplicated in hard copy or machine-readable format without written permission of Adis Data Information BV.

If data is to be distributed under Dialog's Redistribution and Archiving (ERA) policy, distribution is restricted to the company and geographical boundaries of the country where the data was downloaded. Data which has been downloaded under this provision may not be sold or resold to a third pary outside the company organization.


Dialog Standard Terms & Conditions apply.


SAMPLE RECORD [top]

    DIALOG(R)File 107:Adis R&D Insight 
    (c) 2009 Wolters Kluwer Pharma Sol. All rts reserv 
     
  AA=  00244846               014306 
  /NA,NA=  Drug Name: Ezetimibe/simvastatin 
  /TN,TN=   
  RD=  Record Revision Date: 20050323 
     
  /NA,NA=  Brand Name: Inegy(TM); Vytorin(TM); Zintrepid(TM) 
     
  /NA,NA=  Synonyms: Simvastatin/ezetimibe; Zetia(TM)/Zocor sup((R)); Zocor sup((R))/ Zetia(TM) 
  /SY,SY=   
     
  /NA,NA=  Chemical Name: 1-(4-Fluorophenyl)-3(R)-(3(S)-(4-fluorophenyl)-3- hydroxypropyl)-4(S)- 
  /CN,CN=  (4-hydroxyphenyl)azetidin-2-one compd. with Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a- 
    hexahydro-3,7- dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1- naphthalenyl 
      ester,(1S-(1alpha,3alpha,7beta,8beta(2S*,-4S*),8abeta))- 
     
  MF=  Molecular Formula: C49H59F2NO8 
  DR=,RN=  Related CAS® Registry Number: 163222-33-1; 163380-16-3 ((3R-(3alpha(R*),4beta))- 
    isomer); 79902-63-9 
     
  AC=  WHO ATC Code: C10A - Cholesterol and Triglyceride Reducers; C10A-A01 - Simvastatin 
  CC=  EPHMRA ATC Code: C10 - Hypolipidaemics/Anti-Atheroma Preparations; C10A - Cholesterol and 
    Triglyceride Reduction Preparations; C10A1 - HMG CoA reductase inhibitors 
  ME=  Mechanism of Action: HMG-CoA reductase inhibitors; Reductase inhibitors; Oxidoreductase 
    inhibitors; Enzyme inhibitors; Cholesterol absorption inhibitors 
     
  /CO,CO=  Originator Company: Merck/Schering-Plough Pharmaceuticals (USA) 
  /LO,LO=   
  /CO,CO=  Parent Company: Merck & Co - Schering-Plough (JV) 
  /IP,IP=   
     
  DP=  Highest Phase: Launched 
     
  /ST,ST=  Development Status: Launched, Germany, Hypercholesterolaemia 
                        Launched, Mexico, Hypercholesterolaemia 
                        Launched, USA, Hypercholesterolaemia 
                        Registered, European Union, Hypercholesterolaemia 
                        Preregistration, New Zealand , Hypercholesterolaemia 
                        Phase III, USA, Acute coronary syndromes 
     
  /TX,/IT  Text: 
    Introduction: 
    Schering-Plough and Merck & Co. have formed a joint venture, Merck/Schering-Plough 
    Pharmaceuticals, to develop and market ezetimibe and simvastatin as a once-daily fixed- 
    combination tablet (Vytorin(TM), Zintrepid(TM), Inegy(TM)). It is proposed that the 
    combination tablet will be developed for all four doses of simvastatin (10-40mg). Ezetimibe 
    is a cholesterol-absorption inhibitor, whereas simvastatin decreases endogenous liver 
    production of cholesterol by inhibiting HMG-CoA reductase. Combination of these two different 
    cholesterol-lowering mechanisms could achieve additive or synergistic 
    cholesterol-lowering effects. In September 2001, Merck Sharp & Dohme in Singapore opened a 
    manufacturing facility and the plant manufactures the ezetimibe/simvastatin fixed dose tablets. 
                    (...) 
     
  /CS,/TX  Commercial Summary: High cholesterol levels / Cholesterol absorption inhibitor 
      ---------------------------------------------------------------------- 
     Company Region Launch Date Peak Sales Patent Expiry 
      ---------------------------------------------------------------------- 
     Merck US 2004 $2800m 
     Merck ex-US 2004 $1000m 
       Schering Plough US 2004 $2800m 
     Schering Plough ex-US 2004 $1000m 
        ---------------------------------------------------------------------- 
     Copyright (C) Lehman Brothers International. All rights reserved. 
     
  /EV,SC=,EV=  ADIS Evaluation: 
    Hypercholesterolaemia 72 (PO). 
     
     
     
     
     
     
     
  /TX,PO=  Pharmacology Overview: 
     
     Pharmacodynamics: 
     Immunogenicity: 
     Mechanism of action: 
       HMG-CoA reductase inhibitors 
       Reductase inhibitors 
       Oxidoreductase inhibitors 
       Enzyme inhibitors 
       Cholesterol absorption inhibitors 
     Activity versus parent drug: unspecified parent 
     
  /TX,/CV  Clinical Overview: 
    Route(s) of Administration: PO 
     Administration Freq.(per day): 
     Adverse events: 
       rare: Elevated aminotransferase levels, Hepatitis, Musculoskeletal pain, Pancreatitis, 
    Rhabdomyolysis, Thrombocytopenia. 
     Drug Interactions: 
     Unknown. No interaction between ezetimibe and simvastatin in volunteers with LDL cholesterol 
    levels > 130 mg/dl 
     
  /TX,/AE  Adverse Events: 
    Comparative studies: ezetimibe/simvastatin was well tolerated with an overall safety profile 
    similar to atorvastatin monotherapy among 788 patients with hypercholesterolaemia in a 24-week, 
    randomised, placebo- controlled, phase III study. There were no clinically or statistically 
    significant differences in the incidence of muscle enzyme elevations or consecutive liver 
                   (...) 
     
    Drug Interactions: 
    Ezetimibe did not affect the pharmacokinetics of simvastatin in a placebo-controlled phase I 
    study. In this trial, volunteers with LDL cholesterol levels > 130 mg/dl (n = 58) were 
    randomised to receive treatment PO od d1-14 with simvastatin 10mg with or without ezetimibe 
    0.25, 1 or 10mg. There were no significant differences in C sub(max), AUC and CL/F between 
    treatment groups/11/. 
     
    Pharmacokinetics: 
    Pharmacodynamics (Hyperlipidaemia): 
    In a study, 24 volunteers with LDL cholesterol levels > 130 mg/dL were randomised to receive 
    ezetimibe 10mg, simvastatin 20mg, or a combination of the two, for 14 days. The 
    coadministration of ezetimibe and simvastatin was well tolerated and decreased LDL-cholesterol 
    and total cholesterol, compared with simvastatin or ezetimibe alone/12/. 
     
  /TX,/TR  Therapeutic Trials: 
    Hyperlipidaemia: 
    The efficacy and safety of ezetimibe and simvastatin co-administration was assessed in 100 
    patients with heterozygous familial hypercholesterolaemia, coronary heart disease, or multiple 
    cardiovascular risk factors. While on simvastatin 20 mg/day, patients were randomised to 
                   (...) 
     
  /UP,UP=  Drug Update Information: 
     10-Feb-2003: A clinical study hasbeen added to the Hyperlipidaemia pharmacodynamics section (924160) 
     14-Dec-2001: Investigation in Hypercholesterolaemia in USA (PO) 
     13-Dec-2001: Financial Figures have been added 
     04-Dec-2001: Sales forecasts reviewed by Lehman Brothers 
     26-Jul-2000: Investigation in Hypercholesterolaemia in USA (PO) 
     26-Jul-2000: New profile 
     
  /CR,CR=  References: 
    1. Merck/Schering-Plough Pharmaceuticals. Merck/Schering-Plough Pharmaceuticals Announces Submission of New Drug 
    Application to FDA for Ezetimibe/Simvastatin Tablet, an Investigational Cholesterol-Lowering Medicine. Media 
    Release. : 17 Nov 2003. Available from: URL: http://www.merck.com. (English). 
    2. Schering-Plough Corporation. Schering-Plough Reports Financial Results for 2003 Fourth Quarter, Full Year. Media 
                   (...) 
     
  XR=  References No.: 800974093; 800974092; 800974094; 809041635; 800823732; 800934101; 809041121 
     


BASIC INDEX [top]

SEARCH
SUFFIX
DISPLAY
CODE
FIELD NAME
INDEXING
SELECT EXAMPLES
None None All Basic Index Fields Word S GERMANY
/AE AE Adverse Effects Text1 Word S ADVERSE(W)EVENT?/AE
/CN CN Chemical Name2 Word S HYDROXYPHENYL(W)AZETIDIN/CN
/CO CO Company Name2,3 Word S MERCK(W)SCHERING/CO
/CR CR References2 Word S ANNOUNCE?(W)SUBMISSION?/CR
/CS CS Commercial Summary1 Word S CHOLESTEROL(W)ABSORPTION/CS
/CV CV Clinical Overview1 Word S MUSCULOSKELETAL(W)PAIN/CV
/EV EV Adis Evaluation2,4 Word S HYPERCHOLESTEROLAEMIA(S)72/EV
/IP IP Parent Company Name2 Word S MERCK/IP
/IT IT Introductory Text1 Word S CHOLESTEROL(W)LOWERING/IT
/LI LI Licensee2 Word S ASTRA/LI
/LO LO Originator Company Name2 Word S MERCK(W)SCHERING/LO
/NA NA Drug Name2,5 Word
& Phrase
S EZETIMIBE/NA
S 'ZETIMIBE/SIMVASTATIN'/NA
/PC PC Pharmacology Text1 Word S RESISTANT(W)ENTEROCOCCI/PC
/PO PO Pharmacology Overview1 Word S REDUCTASE(W)INHIBITOR?/PO
/RR RR Related CAS Registry Numbers Phrase S 163222-33-1/RR
/ST ST Development Status2 Word S BACTERIAL(W)INFECTIONS/ST
/SY SY Synonyms2 Word
& Phrase
S ZETIA/SY
S ZOCOR SUP?/SY
/TN TN Brand Name2 Word S INEGY/TN
/TR TR Therapeutic Trial Text1 Word S CORONARY(W)HEART/TR
/TX TX Text6 Word S LIVER(W)PRODUCTION/TX
/UP UP Drug Update Information2 Word S CLINICAL(W)STUDY/UP

1 Also searchable and displayable with TX.

2 Searchable in the Basic Index and in the Additional Indexes.

3 Includes Originator, Parent Company, Other Companies, and Licensee.

4 Enter HELP EVAL 107 to see descriptions online.

5 Includes Brand Name, Chemical Name, and Synonyms.

6 /TX includes: AE, CS, CV, IT, PC, PO, TR.


ADDITIONAL INDEXES [top]

SEARCH
PREFIX
DISPLAY
CODE
FIELD NAME
INDEXING
SELECT EXAMPLES
AA= AA IP Accession Number Phrase S AA=004877
AC= AC WHO ATC Codes and Descriptions7 Word
& Phrase
S AC=(TRIGLYCERIDE(W)REDUCER)
S AC='CHOLESTEROL AND TRIGLYCERIDE'?
AM= PO Active Metabolites Phrase S AM=NO
None AN DIALOG Accession Number
CC= CC EphMRA ATC Codes and Descriptions7 Word
& Phrase
S CC=(REDUCTASE(W)INHIBITORS)
S CC=C10A1
CC= CC EphMRA ATC Codes and Descriptions7 Phrase S CC='HYPOLIPIDAEMICS/ANTI-ATHEROMA'?
CN= CN Chemical Name2,11 Phrase S CN=1-(4-FLUOROPHENYL)?
CO= CO Company Name2,3 Phrase S CO=MERCK & CO?
CR= CR References2 Word S CR=(ANNOUNCE?(W)SUBMISSION?)
DP= DP Highest Phase of Development Word
& Phrase
S DP=LAUNCHED
S DP=PHASE III
DR= DR Drug of Record CAS Number8 Phrase S DR=163222-33-1
EL= PO Route of Elimination Phrase S EL=RENAL?
EV= EV Adis Evaluation2,4 Phrase S EV=HYPERCHOLESTROLAEMIA(S)72
IP= IP Parent Company Name2 Phrase S IP=MERCK & CO - SCHERING?
LI= LI Licensee2 Phrase S LI=ASTRA?
LK= PO Linear Kinetics Phrase S LK=YES
LO= LO Originator Company Name2 Phrase S LO='MERCK/SCHERING'?
ME= ME Mechanism of Action Word
& Phrase
S ME=(REDUCTASE(W)INHIBITORS)
S ME=CHOLESTEROL ABSORPTION?
MF= MF Molecular Formula Phrase S MF=C49H59F2NO8
NA= NA Drug Name2,5 Phrase S NA=ZINTREPID(TM)
RD= RD Record Revision Date9,10 Phrase S RD=20050323
RN= RN CAS(R) Registry Number12 Phrase S RN=79902-63-9
SC= SC Adis Rating of Therapeutic Value Numeric S SC>=70(S)EV=HYPERCHOLESTEROLAEMIA
ST= ST Development Status2 Phrase S ST=PREREGISTRATION NEW ZEALAND?
SY= SY Synonyms2,11 Phrase S SY=ZETIA(TM)?
TN= TN Brand Name2,11 Phrase S TN=INEGY(TM)
UD= None Update Phrase S UD=9999
UP= UP Drug Update Information2 Word S UP=(FINANCIAL(W)FIGURES)
XR= XR Reference Number Phrase S XR=800974093

7 Codes are assigned by Adis. Enter HELP CODES 107 to view codes online.

8 Also is searchable as RN=

9 Revision Date is changed only when there are significant changes in the content of the record.

10 Also searchable as PD=

11 Also searchable as NA=

12 Includes drug of record CAS Registry Number and Related CAS Registry Number.


SORT [top]

SORTABLE FIELDS EXAMPLES
AC, CC, CO, LO, ME, NA, RD, SC SORT S2/ALL/CC
SORT S3/ALL/SC


RANK [top]

RANK FIELDS EXAMPLES
All phrase- and numeric-indexed fields in the Additional Indexes can be ranked. RANK CO S3


MAP [top]

MAP FIELDS EXAMPLES
LO, NA, RN, SY, SYRN, XR MAP NA TEMP S2
MAP SYRN TEMP S1


USER-DEFINED FORMAT OPTIONS [top]

User-defined formats can be specified using the display codes indicated in the Search Options tables. TYPE S3/NA,AE,RR/1-5
PRINT S2/NA,SY,SC/ALL


PREDEFINED FORMAT OPTIONS [top]

NO.
DIALOGWEB
FORMAT
RECORD CONTENT
1 -- DIALOG Accession Number
2 -- Drug Name, Synonyms, Brand Name, Chemical Name, Originator Company, Parent Company, Licensee, Other Company, Highest Phase, WHO ATC Codes, EphMRA ATC Codes, and Record Revision Date
3 Medium Development Status, Adis Evaluation, Commercial Summary, Clinical Overview, Pharmacology Overview, Mechanism of Action, Introduction Text, and all information provided in Format 2
4 -- Full Record with Tagged Fields
5 -- Full Record
6 Free Drug Name and Record Revision Date
7 Long Full Record except CAS Registry Number, Related CAS Registry Number, Molecular Formula, References, and Reference Numbers
8 Short Drug Name and Record Revision Date
9 Full Full Record
K -- KWIC (Key Word In Context) displays a window of text; may be used alone or with other formats


DIRECT RECORD ACCESS [top]

FIELD NAME EXAMPLES
DIALOG Accession Number TYPE 00123456/9
DISPLAY 00238215/5
PRINT 00654321/4


Rates [top]

Rates For File: Adis R&D Insight[107]
Cost per DialUnit:                $14.43
Cost per minute:                   $3.83
Rank Elements                      $0.00
ALERT (default)                    $8.50
ALERT (Monthly)                *  $22.00
ALERT (Biweekly/twice a month) *  $13.75
ALERT (Weekly)                     $8.50
ALERT (Daily)                  *   $8.50
ALERT (Calendar weekly)        *   $8.50
ALERT (Intraday)               *   $8.50
* = custom scheduled Alerts only
ALERT Number of included prints        0

Format    Types   Prints
     1    $0.00    $0.00
     2   $11.00   $11.00
     3   $23.00   $23.00
     4   $30.00   $30.00
     5   $30.00   $30.00
     6    $0.00    $0.00
     7   $23.00   $23.00
     8    $0.00    $0.00
     9   $30.00   $30.00
KWIC95    $3.00       NA
KWIC96    $3.00       NA

REDIST/COPY Multiplier Table:

      Range      Multiplier
        1-2       1.00
       3-25       1.50
     26-100       3.00
    101-200       4.00
    201-500       6.00
   501-1000       8.00
 1001 or more    10.00

ARCHIVE Multiplier Table:

      Range      Multiplier
       1-25       1.50
     26-200       3.00
    201-500       6.00
   501-1000       8.00
 1001 or more    10.00
Rates For File: Adis R&D Insight - subscribers[907]
Cost per DialUnit:                $14.00
Cost per minute:                   $3.83
Rank Elements                      $0.00
ALERT (default)                    $8.50
ALERT (Monthly)                *  $22.00
ALERT (Biweekly/twice a month) *  $14.00
ALERT (Weekly)                     $8.50
ALERT (Daily)                  *   $8.50
ALERT (Calendar weekly)        *   $8.50
ALERT (Intraday)               *   $8.50
* = custom scheduled Alerts only
ALERT Number of included prints        0

Format    Types   Prints
     1    $0.00    $0.00
     2    $4.00    $4.00
     3    $4.00    $4.00
     4    $4.00    $4.00
     5    $4.00    $4.00
     6    $0.00    $0.00
     7    $4.00    $4.00
     8    $0.00    $0.00
     9    $4.00    $4.00
KWIC95    $0.40       NA
KWIC96    $0.40       NA

REDIST/COPY Multiplier Table:

      Range      Multiplier
        1-2       1.00
       3-25       1.50
     26-100       3.00
    101-200       4.00
    201-500       6.00
   501-1000       8.00
 1001 or more    10.00

ARCHIVE Multiplier Table:

      Range      Multiplier
       1-25       1.50
     26-200       3.00
    201-500       6.00
   501-1000       8.00
 1001 or more    10.00
[top]



All contents Copyright © Dialog, LLC. All rights reserved.
If you have any questions about, problems with, or corrections for our Web site,
please contact Customer Service for assistance.